Arthroscopically Assisted Versus Open Surgical Reduction of the Hip in Patients With Irreducible DDH Before the Walking Age

May 8, 2024 updated by: Mohamed Mahmoud Ebrahim Abd Allah, Assiut University
To determine the role of arthroscopy in treatment of the DDH.

Study Overview

Detailed Description

  • The term developmental dysplasia of the hip (DDH) is composed of a spectrum of pathologies from stable acetabular dysplasia (femoral head centered in acetabulum but acetabulum is shallow) to concentric hips that are unstable (femoral head can be moved in and out of the confines of the acetabulum) and frankly dislocated hips in which there is a complete loss of contact between the femoral head and acetabulum.
  • Open reduction , traditionally through a Smith - Peterson approach should be considered only if closed reduction cannot be performed.
  • Medial open surgical reduction is a choice for the management of patients younger than 18 months with DDH. The minimal incision and minimal blood loss are advantages of this approach. Limited exposure of the hip joint is a disadvantage.
  • The arthroscopic procedure was reported to represent a meaningful alternative to the open procedure due to a lower complication rate, a safe setting, a lower rate of residual dysplasia, no observed redislocation and low rate occurrence of osteonecrosis.
  • All the intra-articular structures (hypertrophic ligamentum teres, transverse acetabular ligament, and pulvinar tissue) in the acetabulum that impede the reduction of the femoral head could be eliminated by using the arthroscopic technique.

Study Type

Interventional

Enrollment (Estimated)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: mohamed Abd El- Radi, dr
  • Phone Number: 01225338766
  • Email: mradi@aun.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Description

  • Inclusion Criteria:
  • Age: - from nine months to 18 months.
  • Irreducible Hip Dislocation.
  • Exclusion Criteria:
  • Patient age: below 9 months or above 18 months.
  • Teratologic hip dislocation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1 .Arthroscopically assisted
Arthroscopically assisted in surgical reduction of the hip in patients with irreducible DDH before the walking age arm 1
Arthroscopically-Assisted reduction through anterolateral portal for visualization and other accessory portals for instrumentation to achieve reduction and postoperative immobilization in a hip spica.
Other Names:
  • arthroscopically assisted surgical reduction
Active Comparator: 2.open surgical reduction arm 2
open surgical reduction of the hip in patients with irreducible DDH before the walking age arm 2
Open reduction through a bikini incision anterior approach and postoperative immobilization in a hip spica.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Determination the success of reduction and incidence of redislocation rate
Time Frame: immediately postoperative
Documentation of concentric reduction of the hip in immediate postoperative MRI as an assessment tool for the success of the procedure.
immediately postoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of the cosmetic appearance .
Time Frame: 3 month follow up
Documentation the wound size after 3 months follow up in clinical examination as an assessment tool of cosmotic appearance
3 month follow up
Assessment of the shortening
Time Frame: 1 year follow up
Assessment the incidence of leg length discrepancy and shortening that affect walking after one year follow up in clinical examination and x-ray as an assessment tool of shortening
1 year follow up
Assessment the incidence stiffness and decrease range of motion of the affected hip
Time Frame: 1 year follow up
documentation the range of motion of the affected hip and incidence of stiffness after 6 months follow up in clinical examination as an assessment tool of stiffness.
1 year follow up
Assessment the incidence of avascular necrosis in the affected hip
Time Frame: 1 year follow up
documentation the incidence of avascular necrosis of the affected head of hip after one year follow up in clinical examination and x-ray
1 year follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Nariman aboloyoun, Ass.Prof, Orthopedic and Trauma surgery at assiut university hospital
  • Study Director: Hatem Galal El-Din Zaki, prof, Orthopedic and Trauma surgery at assiut university hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 15, 2024

Primary Completion (Estimated)

October 15, 2025

Study Completion (Estimated)

December 15, 2025

Study Registration Dates

First Submitted

April 15, 2024

First Submitted That Met QC Criteria

May 8, 2024

First Posted (Actual)

May 10, 2024

Study Record Updates

Last Update Posted (Actual)

May 10, 2024

Last Update Submitted That Met QC Criteria

May 8, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Developmental Dysplasia of the Hip

Clinical Trials on arthroscopically assisted

3
Subscribe